Please use this identifier to cite or link to this item:
Title: Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update.
Authors: Blanco, Ignacio
Bueno, Patricia
Diego, Isidro
Pérez-Holanda, Sergio
Casas-Maldonado, Francisco
Esquinas, Cristina
Miravitlles, Marc
Keywords: SERPINA1;alpha-1 antitrypsin deficiency;genetic epidemiology;geographic information system;inverse distance weighted interpolation;protease inhibitor
metadata.dc.subject.mesh: Gene Frequency
Genetic Predisposition to Disease
Genetics, Population
Global Health
Models, Genetic
Molecular Epidemiology
alpha 1-Antitrypsin
alpha 1-Antitrypsin Deficiency
Issue Date: 13-Feb-2017
Abstract: In alpha-1 antitrypsin deficiency (AATD), the Z allele is present in 98% of cases with severe disease, and knowledge of the frequency of this allele is essential from a public health perspective. However, there is a remarkable lack of epidemiological data on AATD worldwide, and many of the data currently used are outdated. Therefore, the objective of this study was to update the knowledge of the frequency of the Z allele to achieve accurate estimates of the prevalence and number of Pi*ZZ genotypes worldwide based on studies performed according to the following criteria: 1) samples representative of the general population, 2) AAT phenotyping characterized by adequate methods, and 3) measurements performed using a coefficient of variation calculated from the sample size and 95% confidence intervals. Studies fulfilling these criteria were used to develop maps with an inverse distance weighted (IDW)-interpolation method, providing numerical and graphical information of Pi*Z distribution worldwide. A total of 224 cohorts from 65 countries were included in the study. With the data provided by these cohorts, a total of 253,404 Pi*ZZ were estimated worldwide: 119,594 in Europe, 91,490 in America and Caribbean, 3,824 in Africa, 32,154 in Asia, 4,126 in Australia, and 2,216 in New Zealand. In addition, the IDW-interpolation maps predicted Pi*Z frequencies throughout the world even in some areas that lack real data. In conclusion, the inclusion of new well-designed studies and the exclusion of the low-quality ones have significantly improved the reliability of results, which may be useful to plan strategies for future research and diagnosis and to rationalize the therapeutic resources available.
metadata.dc.identifier.doi: 10.2147/COPD.S125389
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5315200.pdf11,19 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons